An Investigational Drug in Patients With Osteoarthritis (0663-073)

Organon

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis

Treatments: Drug: Comparators: ibuprofen and placebo; Drug: MK0663, etoricoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092755

0663-073

2004_056

Details and patient eligibility

About

This study was conducted to assess the safety and tolerability of an investigational drug and to evaluate its effectiveness in the treatment of osteoarthritis of the hip or knee in both men and women.

Full description

The duration of treatment is 12 weeks.

Enrollment: 548 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with osteoarthritis of the hip or knee who use current approved medication (nonsteroidal anti-inflammatory drugs (NSAIDs)) or tylenol to treat the symptoms of their osteoarthritis. Patients taking NSAIDs are required to discontinue using these drugs and their symptoms must become worse.

Exclusion criteria

• Patients with certain medical conditions may not be allowed to participate. These conditions will be reviewed with the study physician.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind